The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2021 | Mechanism of action of bomedemstat
Harinder Gill, MBBS, PDipID, MD, MRCP, FRCP, FRCPath, FHKCP, FHKAM, The University of Hong Kong, Hong Kong, outlines the mechanism of action of bomedemstat. Lysine-specific demethylase-1 (LSD1) is an enzyme crucial for malignant stem cells and differentiation. Bomedemstat, an orally active LSD1 inhibitor, blocks these actions, allowing progenitors to mature to megakaryocytes. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
